BioVex
Latest round
- Series F
Last raised
- Nov 2009
Total raised
- $138M
Investors
- 20
About BioVex
BioVex, Inc.Founded in 1999 and headquartered in Woburn, US, BioVex, Inc. focuses on delivering biotechnological products and services. In January 2011, Amgen acquired BioVex for an initial cash payment of USD 425 million, with potential milestone payments. The company has successfully completed 8 deals, with the most recent deal occurring on December 28, 2015.com specializes in the development and delivery of innovative biotechnological products and services aimed at addressing critical challenges in healthcare and research. The company’s core offerings include advanced therapeutic solutions that target specific medical conditions, enhancing patient outcomes through precision medicine. These products are designed to cater to a diverse client base, including hospitals, research institutions, and pharmaceutical companies, as well as providing direct solutions for healthcare professionals. Biovex's products have been strategically released over the last few years, expanding their footprint in key geographical markets such as North America, Europe, and parts of Asia.Biovex generates revenue through a structured transaction model that primarily includes direct sales to healthcare providers and partnerships with research institutions. The company’s revenue streams are derived from the sale of its flagship therapeutic products, which are offered on a subscription basis to ensure continuous access and support for its clients. Pricing plans are designed to accommodate various client needs, ranging from individual healthcare providers to large medical facilities, ensuring flexibility and scalability in its offerings. Additionally, Biovex pursues collaborative agreements with pharmaceutical companies, which further enhances its revenue potential through joint ventures and shared research initiatives.BioVex is actively working on the development of new therapeutic products aimed at improving patient care and treatment efficiency, although specific release dates are not provided. The company plans to expand its offerings into emerging markets in Asia and Latin America by the end of 2023, aiming to increase its global presence.1 million from milestone payments, will be utilized to support product development and market expansion efforts, enabling BioVex to enhance its capabilities in delivering innovative solutions to a wider audience.
Who invested in BioVex
20 investors across 6 rounds
See all investors in BioVex
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BioVex
Who invested in BioVex?
BioVex has 20 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioVex raised?
BioVex has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did BioVex last raise money?
BioVex's most recent round on record is a Series F, in Nov 2009.
What does BioVex do?
BioVex is a biotechnology company.
Where is BioVex headquartered?
BioVex is headquartered in Woburn, US.
Which VCs invest in companies like BioVex?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at BioVex's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series F
Raising like BioVex? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.